GLP-1 Brazil Tracker: Discounting Unleashed: Ozivy Drives First Wave of Price Cuts

Research evidence excerpt

GLP-1 Brazil Tracker: Discounting Unleashed: Ozivy Drives First Wave of Price Cuts

UpdateMsemaglutide copy launches.

DTC GLP-1 Channels Could Pressure RADL; Lilly Tactical Replication Is the Key

Risk. Novo Nordisk’s launch of NovoCare Farmácia in Brazil introduces a potential

alternative channel for GLP-1 distribution, but the near-term risk to RADL appears

manageable unless Lilly adopts a similar model. According to Panorama

Farmacêutico, NovoCare Farmácia allows patients to buy Ozempic, Wegovy, and

Rybelsus online with digital prescription validation. Novo is positioning the initiative

as a pilot and complementary channel, rather than a replacement for pharmacies,

and is using a licensed pharmacy partner to comply with Brazilian regulation.

• The model is not easy for pharmaceutical companies to scale broadly.

Brazilian regulation still requires a licensed pharmacy partner, limiting true

direct sales through open marketplaces such as Amazon or Mercado Livre. In

addition, pharmacy traffic is supported by basket economics: consumers

often purchase multiple products per visit, which reduces the attractiveness

of bypassing drugstores for many drug therapeutical areas.

• GLP-1s are a more credible exception. These drugs are high-ticket,

prescription-driven, and often purchased as standalone items, making direct-

to-consumer economics more compelling than in lower-value or basket-

dependent therapeutical areas. If Novo’s alternative channel offers better

pricing, convenience, or adherence support, it could divert some GLP-1

volumes away from traditional drugstores, creating an incremental headwind

for RADL.

• The more material risk would be replication by Lilly. Novo’s GLP-1

portfolio is likely to become less differentiated as Lilly gains share and